BionicM Earns FDA Registration and Class II Exempt Device Listing for Bio Leg™; Its New Motor-Robotic Prosthetic Knee

Summation

  • Bio Leg™ bends the knees with power and actualizes graceful walking without stumbling, even when walking slowly or in small steps, by using power to bend the knees and lift the toes from the ground during the swing phase.
  • Another functional benefit is to provide an easier sit to stand feature giving the user a quicker and smoother transition when standing up from a chair.
  • Bio Leg™ provides an easier sit to stand feature giving the user a quicker and smoother transition when standing up from a chair.

BionicM, an innovative Japanese medical device startup, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) 510(k) exemption registration for Bio Leg™; its robotic prosthetic knee. This registration marks a significant milestone in the company’s commitment to deliver its robotic prosthetic knee to the USA market in 2024 with Japanese-proven technologies.

“Having your limbs amputated severely limits your life,” says Xiaojun Sun, CEO of BionicM, and an above-knee amputee. “While prosthetic limbs have been developed, there are many new ways to improve the lives of amputees with advanced technology. This milestone of achieving our FDA registration underscores our dedication to developing state-of-the-art prosthetic solutions that have the potential to revolutionize mobility of people who have limb loss.”

Video

“Bio Leg is a groundbreaking prosthetic knee joint which can help improve the daily activities of limb loss in transfemoral patients. We have done several trial fittings in my New York facility with very good results,” says Gary Marano, CPO, LPO and CEO of OTF Prosthetics and Orthotics in New York. “Bio Leg allows a more natural gait to walk long distances more efficiently along with stability using ramps and inclines. Another functional benefit is to provide an easier sit to stand feature giving the user a quicker and smoother transition when standing up from a chair.”

Xiaojun Sun; CEO of BionicM, and an above-knee amputee.

Bio Leg features include:

  • Bio Leg assists a wide range of movements with power, such as ascending and descending stairs and sitting on and standing up from a chair.
  • Bio Leg bends the knees with power and actualizes graceful walking without stumbling, even when walking slowly or in small steps, by using power to bend the knees and lift the toes from the ground during the swing phase.
  • Bio Leg prevents knee buckling by assisting the extension of the knee during the stance phase. Users can safely put their weight on the prosthetic leg.
  • Bio Leg provides an easier sit to stand feature giving the user a quicker and smoother transition when standing up from a chair; this feature will also assist those who have had a stroke, weakness, or arthritis in the hip or knee

The company will also be showcasing Bio Leg at the upcoming AOPA Conference in Indianapolis in September.

Other FDA News of Interest

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy